Proprietary fermentation-based pathway performs at scale and delivers highly pure, consistent, and natural CBG, CBC, CBD, CBDA, and CBDV
BERKELEY, Calif.–(BUSINESS WIRE)–Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has successfully completed commercial-scale, fermentation-based production campaigns for its Lygos CBx cannabinoid products, including CBG (cannabigerol), CBC (cannabichromene), CBD (cannabidiol), and CBDA (cannabidiolic acid). These campaigns validate the company’s ability to produce a variety of high-quality cannabinoids and cannabinoid-based products for a growing number of recreational, health & wellness, and pharmaceutical applications, all in an environmentally safe, sustainable, and cost-effective manner.
The company also recently demonstrated the ability to produce CBDV (cannabidivarin) and plans to expand its offerings to include other products that fall within the “varin” cannabinoid class. With these campaigns, Lygos CBx has demonstrated an ability to control many forms of cannabinoid structure with respect to the acidic vs neutral form, terpenoid variants, and alkyl chain length.
“Lygos’ leading sustainable production technology provides a high-performance and on-demand alternative to agricultural-based cannabinoid production,” said Eric Steen, PhD, CEO of Lygos. “With these recent production and scalability milestones, we continue to showcase our innovation beyond the plant and demonstrate our ability to provide high-quality, traceable, and natural cannabinoids with bioidentical equivalent performance. Together with our partners, we are now uniquely positioned to capitalize on the many high-growth opportunities around the world for CBD and these varin-derivatives.”
Lygos CBx’ novel fermentation-based pathway enables the production of highly pure, bio-based cannabinoids. According to a study in Frontiers in Genetics, traditional plant-based CBD production requires heavy use of fertilizers, pesticides, energy, and water, and often results in THC levels that exceed the regulatory limits for many commercial applications. Purely synthetic cannabinoid production can also contain halogenated impurities, which can be toxic to humans and other animals. The Lygos technology produces precise, specific, and isolated cannabinoids and avoids issues of separation, purification, and environmental concerns compared to plant-based production. The production platform features important quality control measures that eliminate THC and other harmful contaminants. The modular platform has been used to produce a variety of natural molecules in both acidic and decarboxylated forms and create cannabinoid-like derivatives for pharmaceutical applications that target the human endocannabinoid system.
Lygos currently offers a full menu of common, rare or novel cannabinoids, along with leading bulk supply, formulation, custom synthesis, and efficacy services to help meet the particular needs of its current and future customers in consumer products and pharmaceuticals industries. Lygos is actively collaborating and co-developing cannabinoid-based products with industry-leading companies. The company plans to launch additional consumer products in the coming year.
About Lygos CBx
Lygos CBx is a Lygos company focused on low-cost, industrial-scale production of a wide range of high-quality, pure, and sustainable cannabinoid compounds that are not easily accessible through traditional agricultural means. The cannabinoids are designed to enhance numerous consumer products, as well as health & wellness and pharmaceutical applications. For more information, visit cbx.lygos.com.
Lygos has created a full-stack biological engineering platform focused on organic acid specialty ingredients, health & wellness ingredients, including cannabinoids and bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive, environmentally degrading alternatives from traditional industrial suppliers, enabling customers to create better, safer products with value-added performance. For more information, visit www.lygos.com and follow us @LygosBiotech.
*Lygos CBx CBD product has been measured as ‘non-detect’ THC by an independent cannabis testing laboratory using a sensitive technique with a detection limit of 2 ppm (2mg/kg).
Lygos, Lygos CBx, and the Lygos and Lygos CBx logos are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.